{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T21:20:36Z","timestamp":1753737636880,"version":"3.40.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of china","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"DOI":"10.1186\/s12920-025-02128-1","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T09:48:13Z","timestamp":1743414493000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Causal association between non-steroidal anti-inflammatory drugs use and the risk of benign prostatic hyperplasia: a univariable and multivariable Mendelian randomization study"],"prefix":"10.1186","volume":"18","author":[{"given":"Zi-He","family":"Peng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Xin","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Hao","family":"Dou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tie","family":"Chong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao-Lun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"issue":"4","key":"2128_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/bju.15229","volume":"127","author":"CM Devlin","year":"2021","unstructured":"Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia - what do we know? BJU Int. 2021;127(4):389\u201399.","journal-title":"BJU Int"},{"issue":"11","key":"2128_CR2","doi-asserted-by":"publisher","first-page":"e754","DOI":"10.1016\/S2666-7568(22)00213-6","volume":"3","author":"AF Awedew","year":"2022","unstructured":"Awedew AF, Han H, Abbasi B, Abbasi-Kangevari M, Ahmed MB, Almidani O, et al. The global, regional, and National burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the global burden of disease study 2019. Lancet Healthy Longev. 2022;3(11):e754\u201376.","journal-title":"Lancet Healthy Longev"},{"doi-asserted-by":"crossref","unstructured":"Miernik A, Gratzke C. Current treatment for benign prostatic hyperplasia. Deutsches \u00c4rzteblatt international; 2020.","key":"2128_CR3","DOI":"10.3238\/arztebl.2020.0843"},{"issue":"3","key":"2128_CR4","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ajur.2017.06.004","volume":"4","author":"KB Lim","year":"2017","unstructured":"Lim KB. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol. 2017;4(3):148\u201351.","journal-title":"Asian J Urol"},{"issue":"2","key":"2128_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/MOU.0000000000000369","volume":"27","author":"G Gandaglia","year":"2017","unstructured":"Gandaglia G, Zaffuto E, Fossati N, Cucchiara V, Mirone V, Montorsi F, et al. The role of prostatic inflammation in the development and progression of benign and malignant diseases. Curr Opin Urol. 2017;27(2):99\u2013106.","journal-title":"Curr Opin Urol"},{"issue":"233","key":"2128_CR6","first-page":"263","volume":"39","author":"\u0141 Dobrek","year":"2015","unstructured":"Dobrek \u0141, Thor PJ. Benign prostatic hyperplasia - progress in pathophysiology and management. Pol Merkur Lekarski. 2015;39(233):263\u201370.","journal-title":"Pol Merkur Lekarski"},{"key":"2128_CR7","doi-asserted-by":"publisher","first-page":"114147","DOI":"10.1016\/j.bcp.2020.114147","volume":"180","author":"S Bindu","year":"2020","unstructured":"Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol. 2020;180:114147.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2128_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/01.ju.0000161598.24740.34","volume":"174","author":"CH Minnery","year":"2005","unstructured":"Minnery CH, Getzenberg RH. Benign prostatic hyperplasia cell line viability and modulation of jm-27 by Doxazosin and ibuprofen. J Urol. 2005;174(1):375\u20139.","journal-title":"J Urol"},{"issue":"5","key":"2128_CR9","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1097\/JU.0000000000000049","volume":"201","author":"GL Lloyd","year":"2019","unstructured":"Lloyd GL, Ricke WA, McVary KT. Inflammation, voiding and benign prostatic hyperplasia progression. J Urol. 2019;201(5):868\u201370.","journal-title":"J Urol"},{"issue":"9","key":"2128_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11934-019-0917-1","volume":"20","author":"GL Lloyd","year":"2019","unstructured":"Lloyd GL, Marks JM, Ricke WA. Benign prostatic hyperplasia and lower urinary tract symptoms: what is the role and significance of inflammation?? Curr Urol Rep. 2019;20(9):54.","journal-title":"Curr Urol Rep"},{"issue":"8","key":"2128_CR11","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/aje\/kwj258","volume":"164","author":"JL St. Sauver","year":"2006","unstructured":"St. Sauver JL, Jacobson DJ, McGree ME, Lieber MM, Jacobsen SJ. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol. 2006;164(8):760\u20138.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"2128_CR12","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/j.1464-410X.2012.11559.x","volume":"111","author":"A Kahokehr","year":"2013","unstructured":"Kahokehr A, Vather R, Nixon A, Hill AG. Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. BJU Int. 2013;111(2):304\u201311.","journal-title":"BJU Int"},{"issue":"4","key":"2128_CR13","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.urology.2008.04.069","volume":"72","author":"S Falahatkar","year":"2008","unstructured":"Falahatkar S, Mokhtari G, Pourreza F, Asgari SA, Kamran AN. Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. Urology. 2008;72(4):813\u20136.","journal-title":"Urology"},{"issue":"1","key":"2128_CR14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.eururo.2004.08.024","volume":"47","author":"F Di Silverio","year":"2005","unstructured":"Di Silverio F, Bosman C, Salvatori M, Albanesi L, Proietti Pannunzi L, Ciccariello M, et al. Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur Urol. 2005;47(1):72\u20138. discussion 8\u20139.","journal-title":"Eur Urol"},{"issue":"2","key":"2128_CR15","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/aje\/kwr524","volume":"176","author":"JM Schenk","year":"2012","unstructured":"Schenk JM, Calip GS, Tangen CM, Goodman P, Parsons JK, Thompson IM, et al. Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2012;176(2):156\u201363.","journal-title":"Am J Epidemiol"},{"issue":"9","key":"2128_CR16","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/pros.23359","volume":"77","author":"LH Nyg\u00e5rd","year":"2017","unstructured":"Nyg\u00e5rd LH, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ. The effect of non-steroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia. Prostate. 2017;77(9):1029\u201335.","journal-title":"Prostate"},{"issue":"9","key":"2128_CR17","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/j.1464-410X.2004.04839.x","volume":"93","author":"D Kang","year":"2004","unstructured":"Kang D, Andriole GL, Van De Vooren RC, Crawford D, Chia D, Urban DA, et al. Risk behaviours and benign prostatic hyperplasia. BJU Int. 2004;93(9):1241\u20135.","journal-title":"BJU Int"},{"issue":"7","key":"2128_CR18","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/j.1464-410X.2011.10867.x","volume":"110","author":"S Sutcliffe","year":"2012","unstructured":"Sutcliffe S, Grubb Iii RL, Platz EA, Ragard LR, Riley TL, Kazin SS, et al. Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the prostate, lung, colorectal, and ovarian cancer screening trial. BJU Int. 2012;110(7):1050\u20139.","journal-title":"BJU Int"},{"issue":"9","key":"2128_CR19","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S0895-4356(01)00351-1","volume":"54","author":"JB Meigs","year":"2001","unstructured":"Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol. 2001;54(9):935\u201344.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"2128_CR20","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.urology.2009.01.088","volume":"74","author":"I Ozdemir","year":"2009","unstructured":"Ozdemir I, Bozkurt O, Demir O, Aslan G, Esen AA. Combination therapy with Doxazosin and tenoxicam for the management of lower urinary tract symptoms. Urology. 2009;74(2):431\u20135.","journal-title":"Urology"},{"issue":"11","key":"2128_CR21","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1681\/ASN.2016010098","volume":"27","author":"P Sekula","year":"2016","unstructured":"Sekula P, Del Greco MF, Pattaro C, K\u00f6ttgen A. Mendelian randomization as an approach to assess causality using observational data. J Am Soc Nephrol. 2016;27(11):3253\u201365.","journal-title":"J Am Soc Nephrol"},{"issue":"R1","key":"2128_CR22","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1093\/hmg\/ddu328","volume":"23","author":"G Davey Smith","year":"2014","unstructured":"Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23(R1):R89\u201398.","journal-title":"Hum Mol Genet"},{"issue":"7","key":"2128_CR23","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/aje\/kwt084","volume":"178","author":"BL Pierce","year":"2013","unstructured":"Pierce BL, Burgess S. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am J Epidemiol. 2013;178(7):1177\u201384.","journal-title":"Am J Epidemiol"},{"doi-asserted-by":"crossref","unstructured":"Emdin CA, Khera AV, Kathiresan S. Mendelian Randomization Jama. 2017;318(19):1925\u20136.","key":"2128_CR24","DOI":"10.1001\/jama.2017.17219"},{"issue":"1","key":"2128_CR25","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1038\/s41467-019-09572-5","volume":"10","author":"Y Wu","year":"2019","unstructured":"Wu Y, Byrne EM, Zheng Z, Kemper KE, Yengo L, Mallett AJ, et al. Genome-wide association study of medication-use and associated disease in the UK biobank. Nat Commun. 2019;10(1):1891.","journal-title":"Nat Commun"},{"doi-asserted-by":"crossref","unstructured":"Zhao JH, Stacey D, Eriksson N, Macdonald-Dunlop E, Hedman \u00c5K, Kalnapenkis A et al. Genetics of Circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets. Nat Immunol. 2023.","key":"2128_CR26","DOI":"10.1038\/s41590-023-01635-6"},{"issue":"7944","key":"2128_CR27","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41586-022-05473-8","volume":"613","author":"MI Kurki","year":"2023","unstructured":"Kurki MI, Karjalainen J, Palta P, Sipila TP, Kristiansson K, Donner KM, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023;613(7944):508\u201318.","journal-title":"Nature"},{"issue":"2","key":"2128_CR28","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jamapsychiatry.2020.3554","volume":"78","author":"DB Rosoff","year":"2021","unstructured":"Rosoff DB, Smith GD, Lohoff FW. Prescription opioid use and risk for major depressive disorder and anxiety and Stress-Related disorders: A multivariable Mendelian randomization analysis. JAMA Psychiatry. 2021;78(2):151\u201360.","journal-title":"JAMA Psychiatry"},{"key":"2128_CR29","doi-asserted-by":"publisher","first-page":"329456","DOI":"10.1155\/2014\/329456","volume":"2014","author":"G Corona","year":"2014","unstructured":"Corona G, Vignozzi L, Rastrelli G, Lotti F, Cipriani S, Maggi M. Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. Int J Endocrinol. 2014;2014:329456.","journal-title":"Int J Endocrinol"},{"issue":"2","key":"2128_CR30","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4103\/0970-1591.126900","volume":"30","author":"ND Patel","year":"2014","unstructured":"Patel ND, Parsons JK. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian J Urol. 2014;30(2):170\u20136.","journal-title":"Indian J Urol"},{"issue":"5","key":"2128_CR31","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10654-017-0255-x","volume":"32","author":"S Burgess","year":"2017","unstructured":"Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32(5):377\u201389.","journal-title":"Eur J Epidemiol"},{"issue":"2","key":"2128_CR32","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/ije\/dyv080","volume":"44","author":"J Bowden","year":"2015","unstructured":"Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect Estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512\u201325.","journal-title":"Int J Epidemiol"},{"issue":"4","key":"2128_CR33","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/gepi.21965","volume":"40","author":"J Bowden","year":"2016","unstructured":"Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40(4):304\u201314.","journal-title":"Genet Epidemiol"},{"issue":"21","key":"2128_CR34","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1002\/sim.6522","volume":"34","author":"MF Greco","year":"2015","unstructured":"Greco MF, Minelli C, Sheehan NA, Thompson JR. Detecting Pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Stat Med. 2015;34(21):2926\u201340.","journal-title":"Stat Med"},{"issue":"5","key":"2128_CR35","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","volume":"50","author":"M Verbanck","year":"2018","unstructured":"Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal Pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693\u20138.","journal-title":"Nat Genet"},{"issue":"11","key":"2128_CR36","doi-asserted-by":"publisher","first-page":"e1007081","DOI":"10.1371\/journal.pgen.1007081","volume":"13","author":"G Hemani","year":"2017","unstructured":"Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet. 2017;13(11):e1007081.","journal-title":"PLoS Genet"},{"issue":"5","key":"2128_CR37","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/ije\/dyt179","volume":"42","author":"MJ Brion","year":"2013","unstructured":"Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. Int J Epidemiol. 2013;42(5):1497\u2013501.","journal-title":"Int J Epidemiol"},{"issue":"29","key":"2128_CR38","doi-asserted-by":"publisher","first-page":"4705","DOI":"10.1002\/sim.7492","volume":"36","author":"JMB Rees","year":"2017","unstructured":"Rees JMB, Wood AM, Burgess S. Extending the MR-Egger method for multivariable Mendelian randomization to correct for both measured and unmeasured Pleiotropy. Stat Med. 2017;36(29):4705\u201318.","journal-title":"Stat Med"},{"issue":"4","key":"2128_CR39","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/aje\/kwu283","volume":"181","author":"S Burgess","year":"2015","unstructured":"Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. Am J Epidemiol. 2015;181(4):251\u201360.","journal-title":"Am J Epidemiol"},{"issue":"3","key":"2128_CR40","doi-asserted-by":"publisher","first-page":"155798832311766","DOI":"10.1177\/15579883231176667","volume":"17","author":"G Tang","year":"2023","unstructured":"Tang G, Liu M, Ding G, Liu S, Chu Y, Cui Y, et al. The efficacy of Cyclooxygenase-2 inhibitors for the male treatment of lower urinary tract symptoms: A systematic review and Meta-Analysis. Am J Mens Health. 2023;17(3):15579883231176667.","journal-title":"Am J Mens Health"},{"issue":"13","key":"2128_CR41","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1001\/archinte.165.13.1547","volume":"165","author":"KM Verhamme","year":"2005","unstructured":"Verhamme KM, Dieleman JP, Van Wijk MA, van der Lei J, Bosch JL, Stricker BH, et al. Nonsteroidal anti-inflammatory drugs and increased risk of acute urinary retention. Arch Intern Med. 2005;165(13):1547\u201351.","journal-title":"Arch Intern Med"},{"issue":"5","key":"2128_CR42","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.euf.2021.07.001","volume":"8","author":"S Crisafulli","year":"2022","unstructured":"Crisafulli S, Cutroneo PM, Verhamme K, Ferrajolo C, Ficarra V, Sottosanti L, et al. Drug-induced urinary retention: an analysis of a National spontaneous adverse drug reaction reporting database. Eur Urol Focus. 2022;8(5):1424\u201332.","journal-title":"Eur Urol Focus"},{"issue":"3","key":"2128_CR43","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/S0022-5347(05)64591-0","volume":"168","author":"J Gruenenfelder","year":"2002","unstructured":"Gruenenfelder J, McGuire EJ, Faerber GJ. Acute urinary retention associated with the use of cyclooxygenase-2 inhibitors. J Urol. 2002;168(3):1106.","journal-title":"J Urol"},{"issue":"7","key":"2128_CR44","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/gepi.21758","volume":"37","author":"S Burgess","year":"2013","unstructured":"Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37(7):658\u201365.","journal-title":"Genet Epidemiol"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-025-02128-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-025-02128-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-025-02128-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T12:55:21Z","timestamp":1743512121000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-025-02128-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2128"],"URL":"https:\/\/doi.org\/10.1186\/s12920-025-02128-1","relation":{},"ISSN":["1755-8794"],"issn-type":[{"type":"electronic","value":"1755-8794"}],"subject":[],"published":{"date-parts":[[2025,3,31]]},"assertion":[{"value":"22 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data sources were derived from publicly available summary-level data, so no informed patient consent was required to release the summary-level data. The ethics committee of the Second Affiliated Hospital of Xi\u2019an Jiaotong University waived the need for ethical approval and informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}